Technology transfer programme for influenza vaccines - Lessons from the past to inform the future.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Influenza Vaccine Technology Transfer: A Mixed-Methods Study with Vaccine Manufacturers and Global Experts to Assess Successes, Challenges, and Opportunities.Vaccines · 2026
   Article
2. Economic Evaluation of Pneumococcal Vaccination in Egypt: Cost-Effectiveness, Budget Impact, and Domestic Manufacturing Potential.Vaccines · 2026
   Article
3. Pathways to economically viable and sustainable vaccine manufacturing in LMICs.Vaccine · 2026
   Review
4. Balancing Innovation and Equity: A Successful Dynamic Between Private and Public Sectors Is Essential to Ensure True Pandemic Influenza Preparedness.Vaccines · 2025
   Article
5. Accomplishments and challenges in developing improved influenza vaccines: An evaluation of three years of progress toward the milestones of the influenza vaccines research and development roadmap.Vaccine · 2025
   Review
6. Global production capacity of seasonal and pandemic influenza vaccines in 2023.Vaccine · 2025
   Article
7. 'Our project, your problem?' A case study of the WHO's mRNA technology transfer programme in South Africa.PLOS global public health · 2024
   Article
8. Novel approaches to enable equitable access to monoclonal antibodies in low- and middle-income countries.PLOS global public health · 2024
   Review
9. Clinical and Regulatory Challenges and Opportunities for Monoclonal Antibodies in Low- and Middle-Income Countries: Lessons from COVID-19 and Beyond.Pharmaceutical medicine · 2023
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as